Belgium: Policymakers’ Guide to AI Governance and Competitive Advantage

Belgium faces a unique policy opportunity in 2026. Your capital city hosts the EU AI Office, which is enforcing the EU AI Act across 27 member states. Your semiconductor research through IMEC positions your nation as Europe’s alternative to Asia for AI chip design. Your pharma sector employs 60,000+ people and is deploying AI at enterprise scale. Your port at Antwerp-Bruges is testing autonomous trucks and AI-optimized logistics. And your population, inherently multilingual, is a natural laboratory for multilingual AI systems that will become globally critical. Yet Belgium is only at 28% of companies investing in AI versus 38% across the EU. This gap represents both risk (companies left behind) and opportunity (first-mover advantage for policy-backed initiatives). This brief proposes a policy framework to consolidate Belgium’s AI advantages.

Belgium as the EU AI Regulation Hub

The EU AI Office, headquartered in Brussels, is writing and enforcing the EU AI Act in real-time. This creates a strategic asset: Belgian companies, and Belgian workers, navigate AI regulation with 6-18 months of early clarity compared to competitors elsewhere in Europe. Policy recommendation: formalize Brussels as the AI regulation hub by establishing:

1. The Brussels AI Regulatory Institute (€15 million/year): A public research institution dedicated to AI Act implementation, exempting regulatory research from data protection constraints that block other research. Partner IMEC, KU Leuven, and VUB. Produce quarterly compliance guidance that becomes the de facto standard for European AI companies. This elevates Brussels’s role from regulatory enforcement to regulatory leadership.

2. Fast-Track AI Compliance Certification for Belgian Companies (€3 million/year): Offer EU AI Act compliance audits for Belgian companies at cost (€5,000-€25,000 per audit). Early-mover Belgian companies gain 12-18 months of competitive advantage before their competitors must comply. Certification becomes a market signal that a Belgian company understands regulation better than its European competitors.

3. Attract Regulatory Talent to Brussels (€8 million/year for visa/housing subsidies): The EU AI Office is drawing AI policy experts from across the world. Offer 50-year residency visas (renewable) for AI researchers, policy specialists, and regulatory experts. Building regulatory expertise density in Brussels makes your nation the go-to expertise center for companies navigating AI law across the EU.

Infrastructure Gaps vs. AI Opportunity

Belgium’s digital infrastructure is strong relative to emerging markets but has gaps relative to AI-intensity requirements:

Computational capacity: Belgium has 13 data centers; Germany has 50+. Proposal: Public-Private Partnership funding for 5 new AI-optimized data centers across Belgium (Brussels, Antwerp, Ghent, Liège, Charleroi) with €80 million investment. Target cloud capacity that makes Belgium the preferred EU data location for regulated AI workloads (finance, pharma, government).

5G and edge computing: Complete 5G deployment across Brussels, Antwerp port, and IMEC research facilities by 2027 to enable real-time AI inference for autonomous systems and industrial AI. Budget: €50 million. Partnership with Proximus, Vodafone, and Orange.

AI research infrastructure: IMEC leads, but extend capacity. Fund 2 additional AI research centers (one in Antwerp for maritime/port AI, one in Liège for manufacturing AI) with €60 million total investment. These become centers of gravity for companies building vertical AI solutions.

Pharma & Biotech: Belgium’s AI Edge

Belgium’s pharma and biotech sector (UCB, Sanofi Belgium, etherna RNA therapeutics) has €66.8 billion combined market cap (up 42.7% YoY) and employs 60,000+ people. This sector is deploying AI faster than any other Belgian industry: drug discovery, clinical trial optimization, manufacturing quality, pharmacovigilance. Policy recommendations:

1. Establish a Pharma-AI Innovation Fund (€150 million/5 years): Public funding for Belgian pharma companies deploying AI in drug discovery, clinical trials, and manufacturing. Focus: accelerating time-to-market for AI-designed therapeutics. Belgian companies achieving regulatory approval for AI-discovered drugs will set global precedent and attract investment.

2. Create a Regulatory Sandbox for Pharma AI (€5 million/year): Partner with the European Medicines Agency (headquartered in Amsterdam, but coordinate with Brussels) to establish a regulatory pathway for AI-designed drugs that meet safety standards faster. Belgian pharma companies navigating this sandbox first gain 24-36 months of head-start on competitors.

3. Biotech Visa Program (€4 million/year for 100 visas): Fast-track residency for biotech AI researchers and drug discovery scientists. Target top talent from China, India, US, and Canada who are increasingly exploring European alternatives. Offering them residence in Belgium (with access to Brussels’s EU regulatory environment and IMEC’s research) attracts brain power that strengthens your pharma ecosystem.

Policy Recommendations Summary

Tier 1: Transform Brussels as Global AI Regulation Hub (€26 million/year)

• Establish Brussels AI Regulatory Institute (€15M/year)
• Fast-track compliance certification (€3M/year)
• Regulatory talent attraction (€8M/year)

Tier 2: Build AI-Ready Infrastructure (€190 million over 5 years)

• 5 AI-optimized data centers (€80M)
• Complete 5G edge computing (€50M)
• 2 additional AI research centers (€60M)

Tier 3: Support Pharma/Biotech AI Deployment (€155 million over 5 years)

• Pharma-AI innovation fund (€150M/5 years)
• Regulatory sandbox (€5M/year)
• Biotech visa program (€4M/year)

Tier 4: Multilingual AI as Export Product (€40 million/3 years)

• Fund research into Dutch/French/German/English AI systems at IMEC and universities (€25M)
• Create “Multilingual AI Label” for Belgian companies (€5M marketing)
• Subsidize AI companies that export multilingual systems to emerging markets (€10M/3 years)

Total public investment: €430 million over 5 years. Estimated economic return: €8-12 billion in pharma licensing deals, data governance licensing (Collibra expansion), semiconductor partnerships (IMEC), and AI software exports. This is a 20:1 return ratio, below typical venture returns but with significant risk reduction through diversified bets across regulation, infrastructure, pharma, and semiconductors.

Secondary Recommendation: Multilingual AI Competitive Advantage

The EU AI Act must be enforced in 24 languages. Belgium, with its Dutch/French/German/English multilingual requirement, is a natural leader in multilingual AI systems. Emerging markets in Africa, South Asia, and Southeast Asia will demand multilingual AI by 2030. Belgian companies that build these capabilities early will have unmatched export opportunity. Fund academic research at IMEC, KU Leuven, and VUB specifically focused on multilingual AI. Make Belgium the global leader in this category by 2030.